[
    "/p>\n  DIQMTQSPSSI^SASVGDRVT\u0393\u0393CRASQSIDSYLHWYQQKPGK\u039bPKLLIYSASNLETG VPSRFSGRGSGTDFTLTISSLQPF-DFATWCQQVVWRPFTFGQGTKVEIKR</p>\n  (Compound 137; SEQ ID No:53) DIQMTQSPSSLSAS VGDRVTITCRASQSIDSYLI IWYQQKPGKAPKLLIYSASNLETG VPSRFSGSGSGTDFTLTlSSLVPEDFA'Ti'YCQQVVWRPFTFGQGTKVEIKR (Compound 121 ; ; SEQ ID No:54); and a sequence at least 95%, more preferably at least 96<sup>'</sup>%, 97%, 98% or 99% identical to one of these sequences.</p>\n  In a further preferred embodiment the constant region comprises C<sub>H</sub>2 and C<sub>H</sub>3 domains which together have the following sequence:</p>\n  PEL-LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSl lEDPEVKrN^^YVDG\u03bb\u0395VHNf AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSl^LSPGK; (SEQ ID NO:63)</p>\n  or an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical thereto.</p>\n  In another preferred embodiment the domain antibody construct comprises an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least</p>\n  Or\\O/,, O\u03c2t\u00f8 O\u039biW, OTfSC OQCS, ^v IWOZ i^ni-i\u039bnl u \u03b9l,,\\ /\u201e.,,,,\u201e\u201e\u201e\u201e \u201e\u00ab. .&lt;.-\u201e. *l, .:.,. C\u0393\u039b \u03c4r\\ &gt;\\.\u03c4... &lt; i and most preferably the sequence .set forth i\u03b1 SEQ ID No:ll.</p>\n  Tlie term \"binds to\" as used herein, is intended to refer to the binding of an antigen by an imm unoglobulin variable region with a dissociation constant (Kj) of l\u03bcM or lower as \n\nmeasured by surface plasmon resonance analysis using, for example a BlAcorc\u2122 surface plasmon resonance system and BIAcore\u2122 kinetic evaluation software (eg. version 2.1). The affinity or dissociation constant (Ka)for a specific binding interaction is preferably about 500 nM or lower, more preferably aboul 300 nM or lower and preferably at least 300 nM to 50 pM, 200 nM to 50 pM, and more preferably at least 100 nM to 50 pM, 75 nM to 50 pM, 10 riM to 50 pM.The term \"dAb\" as used herein refers to an antibody single variable domain ( V<sub>H</sub> or VL) polypeptide that specifically binds antigen,</p>\n  In a further preferred embodiment of the present invention the domain antibody construct forms a homo- or heterodimer with another domain antibody construct according to the present invention. Dimcrisation can increase the strength of antigen binding, wherein the strength of binding is related to the suni of the binding affinities of the multiple binding sites. To facilitate ditncr formation, the hinge region of the domain antibody construct comprises at least one, and preferably two, cysteine residues.</p>\n  In a particularly preferred embodim ent of the present invention, lhc domain antibody construct forms a homodimer with an identical domain antibody construct.</p>\n  Accordingly in another aspect the present invention, provides a dimeric domain antibody construct which binds to human TNF-\u03b1 wherein the dimer consists of two domain antibody constructs according to the present invention.</p>\n  Il is preferred that the dimeric domain antibody construct is a homodimer and it is particularly preferred thai the domain antibody constructs making up the homodimer comp"
]